Clinical Edge Journal Scan

Preventive treatment improves cognition and QoL in patients with chronic migraine


 

Key clinical point: Patients with chronic migraine vs healthy controls had highly impaired cognition and worsened quality of life (QoL), which improved after 3 months of treatment with botulinum toxin or oral drugs.

Major finding: Patients with chronic migraine had worse scores than healthy controls for cognition, QoL, and emotional status at baseline (P < .0001), but showed significant improvements in Rey-Osterrieth Complex Figure test memory task (P < .0001), Trail Making Test A attention test (P = .007), and 36-item Short Form Health Survey based QoL measures for bodily pain (P = .040) and general health (P = .003) after 3 months of preventive treatment.

Study details: This observational study analyzed 46 patients with chronic migraine and 50 age- and sex-matched healthy controls for mood, cognition, and QoL before and 3 months after receiving preventive treatment with botulinum toxin or oral drugs.

Disclosures: This study did not declare any specific funding source. The authors declared no conflicts of interest.

Source: González-Mingot C et al. Preventive treatment can reverse cognitive impairment in chronic migraine. J Headache Pain. 2022;23:121 (Sep 15). Doi: 10.1186/s10194-022-01486-w

Recommended Reading

Real-world efficacy and safety of anti-CGRP drugs in drug-resistant chronic migraine
Migraine ICYMI
Commentary: Menstruation, sleep, and visual disturbances in migraine, October 2022
Migraine ICYMI
Headache for inpatients with COVID-19 may predict better survival
Migraine ICYMI
Anti-CGRP receptor mAb increase blood pressure in patients with migraine
Migraine ICYMI
Meta-analysis corroborates evidence on efficacy of onabotulinumtoxinA for chronic migraine
Migraine ICYMI
Real-world efficacy of galcanezumab in high frequency episodic and chronic migraine
Migraine ICYMI
Overlapping initial symptoms demand careful differential diagnosis of migraine and ischemic stroke
Migraine ICYMI
Benefit-risk profiles of lasmiditan, rimegepant, and ubrogepant for acute treatment of migraine
Migraine ICYMI
Association between CGRP-LI levels and migraine treatment outcomes with erenumab
Migraine ICYMI
Changes in gastrointestinal motility with galcanezumab and erenumab in episodic migraine
Migraine ICYMI